Gastrointestinal bleeding after percutaneous coronary intervention

Digestion

Volumn 83, Issue 3, 2011, Pages 153-160

  Tanigawa, Tetsuya ^a   Watanabe, Toshio ^a   Nadatani, Yuji ^a   Otani, Koji ^a   MacHida, Hirohisa ^a   Okazaki, Hirotoshi ^a   Yamagami, Hirokazu ^a   Watanabe, Kenji ^a   Tominaga, Kazunari ^a   Fujiwara, Yasuhiro ^a   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastrointestinal bleeding; Helicobacter pylori; Low dose aspirin; Percutaneous coronary intervention; Proton pump inhibitor; Thienopyridine derivatives

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C19; ENOXAPARIN; FAMOTIDINE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; TICLOPIDINE;

AGING; ANEMIA; ANGIOCARDIOGRAPHY; BLOOD TRANSFUSION; CARDIOGENIC SHOCK; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COLON INJURY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; ENDOSCOPY; ENZYME POLYMORPHISM; ERADICATION THERAPY; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOSPITAL COST; HUMAN; INFECTION RISK; LENGTH OF STAY; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PEPTIC ULCER; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; STABLE ANGINA PECTORIS; STRESS; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION;

ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTESTINES; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TICLOPIDINE;

EID: 79251579612     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321813     Document Type: Conference Paper

References (49)

1. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME: Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005; 112:3306-3313.
2. Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R: Five-year clinicalouttation insights from a patient-level pooled analysis of four randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol 2009; 54:894-902.
3. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of an-tiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308:159-168.
4. Awtry EH, Loscalzo J: Aspirin. Circulation 2000; 101:1206-1218.
5. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
6. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324: 71-86.
7. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420.
8. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA: Effects of pretreatment with clopi-dogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-533.
9. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW: 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary inter-vention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51: 172-1809.
10. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R: Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340:1421-1425.
11. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Hot study group. Lancet 1998; 351: 1755-1762. (Pubitemid 28269185)
12. Serrano P, Lanas A, Arroyo MT, Ferreira IJ: Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002; 16: 1945-1953.
13. Derry S, Loke YK: Risk of gastrointestinal haemorrhage with long-term use of aspirin: meta-analysis. BMJ 2000; 321:1183-1187.
14. Weisman SM, Graham DY: Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162:2197-2202.
15. Abbas AE, Brodie B, Dixon S, Marsalese D, Brewington S, O'Neill WW, Grines LL, Grines CL: Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005; 96: 173-176. (Pubitemid 40978568)
16. Nikolsky E, Stone GW, Kirtane AJ, Dangas GD, Lansky AJ, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, Manoukian SV, White HD, Ohman EM, Bertrand ME, Cox DA, Mehran R: Gastrointestinal bleeding in patients with acute coronary syndromes: Incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 54:1293-1302.
17. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF, Weissman NJ, Lindsay J, Fuchs S: Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92:930-935.
18. Chin MW, Yong G, Bulsara MK, Rankin J, Forbes GM: Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study. Am J Gastroenterol 2007; 102: 2411-2416.
19. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, White K, Goldberg RJ: Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24:1815-1823.
20. Wallace JL: Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 2008; 88: 1547-1565.
21. Cryer B, Feldman M: Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117:17-25.
22. Kauffman G: Aspirin-induced gastric mucosal injury: lessons learned from animal models. Gastroenterology 1989; 96:606-614.
23. Mashita Y, Taniguchi M, Yokota A, Tanaka A, Takeuchi K: Oral but not parenteral aspirin upregulates COX-2 expression in rat stomachs. A relationship between COX-2 expression and PG deficiency. Digestion 2006; 73: 124-132.
24. Delaney JA, Opatrny L, Brophy JM, Suissa S: Drug-drug interactions between antithrom-botic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347-351.
25. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, Andersen M, Lassen AT: Use of single and combined antithrom-botic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333:726.
26. Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL: Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA 2001; 98:6470-6475.
27. Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida Y, Tsukui T, Osawa H, Sakurai Y, Yoshino J, Mizokami Y, Mine T, Arakawa T, Kuwayama H, Saigenji K, Yakabi K, Chiba T, Shimosegawa T, Sheehan JE, Perez-Gutthann S, Yamaguchi T, Kaufman DW, Sato T, Kubota K, Terano A: Case-control study on the association of upper gastrointestinal bleeding and non-steroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 2006; 62: 765-772.
28. Harker LA, Boissel JP, Pilgrim AJ, Gent M: Comparative safety and tolerability of clopi-dogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999; 21: 325-335.
29. Toyokawa T, Inaba T, Ishikawa S, Nakatsu M, Ando M, Tomoda J: Investigation of upper gastrointestinal bleeding after implantation of drug-eluting stents; prospective cohort study. Scand J Gastroenterol 2010; 45: 1097-1100.
30. Ko DT, Yun L, Wijeysundera HC, Jackevicius CA, Rao SV, Austin PC, Marquis JF, Tu JV: Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patient solder than 65 years. Circ Cardiovasc Interv 2010; 3:140-147.
31. Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr: Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contem-porary practice. J Am Coll Cardiol 2009; 53: 2019-2027.
32. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, Stamler JS, Califf RM: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555-1562.
33. Ng FH, Wong SY, Lam KF, Chang CM, Lau YK, Chu WM, Wong BC: Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. Am J Gastroenterol 2008; 103:865-871.
34. Yasuda H, Yamada M, Sawada S, Endo Y, Inoue K, Asano F, Takeyama Y, Yoshiba M: Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. Intern Med 2009; 48: 1725-1730.
35. Juhasz M, Herszenyi L, Tulassay Z: Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist. Digestion 2010; 81: 10-15.
36. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
37. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS: Cytochrome P450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
38. Taha AS, McCloskey C, Prasad R, Bezlyak V: Famotidine for the prevention of peptic ulcers and oesophagitis in patients tak ing low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 119-125.
39. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R: Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16: 779-786.
40. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, Chan HL, Sung JJ: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-973.
41. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, Lau GK, Wong WM, Yuen MF, Chan AO, Lai CL, Wong J: Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-2038.
42. Leung WK, Bjarnason I, Wong VW, Sung JJ, Chan FK: Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet 2007; 369:614. (Pubitemid 46241446)
43. Watanabe T, Sugimori S, Kameda N, Machida H, Okazaki H, Tanigawa T, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Higuchi K, Arakawa T: Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008; 6: 1279-1282.
44. Steinberg DH, Shah P, Kinnaird T, Pinto Slottow TL, Roy PK, Okabe T, Bonello L, de Labriolle A, Smith KA, Torguson R, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Lindsay J, Waksman R: Bleeding risk and outcomes of bivalirudin versus glyco-protein IIB/IIIA inhibitors with targeted low-dose unfractionated heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris. Am J Cardiol 2008; 102:160-164.
45. Overgaard CB, Ivanov J, Seidelin PH, Todorov M, Mackie K, Dzavik V: Thrombocytopenia at baseline is a predictor of in-hospital mortality in patients undergoing percutaneous coronary intervention. Am Heart J 2008; 156:120-124.
46. Bagur R, Bertrand OF, Rodes-Cabau J, Rinfret S, Larose E, Tizon-Marcos H, Gleeton O, Nguyen CM, Roy L, Costerousse O, De Larochelliere R: Comparison of outcomes in patients > or = 70 years versus <70 years after transradial coronary stenting with maximal antiplatelet therapy for acute coronary syndrome. Am J Cardiol 2009; 104: 624-629.
47. Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ: Bleeding risk associated with one year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2009; 157:369-374.
48. Hokimoto S, Matsui K, Oshima S, Noda K, Kaikita K, Sumida H, Sugiyama S, Ogawa H: Effects of gastric medicines on gastroduodena linjury in patients with stable angina during antiplatelet therapy. J Cardiol 2009; 54: 71-75.
49. Jolly SS, Pogue J, Haladyn K, Peters RJ, Fox KA, Avezum A, Gersh BJ, Rupprecht HJ, Yusuf S, Mehta SR: Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J 2009; 30: 900-907.